Expert review of anti-infective therapy · 2026
Clinical use of dalbavancin in Canada: the clear study final results.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhanel George G, Silverman Michael, Bhalla Janhavi, Baxter Melanie, Rahimi Reza, Wong Maggie, Mirzanejad Yazdan, MacLaggan Timothy, Shchepanik Kiarah, Wise Heather, Irfan Neal, Girouard Gabriel, Dhami Rita, Kucey Melissa, Stankus Vida, Schmidt Kristin, Poulin Sébastien, Connors William, Chagla Zain, Serebryanskyy Alex, Tascini Carlo, Tessier Jean-François, Keynan Yoav, Walkty Andrew, Karlowsky James A
Аннотация
BACKGROUND: The CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry collected data on 160 Canadian patients who received dalbavancin between January 2023 and December 2025.
RESEARCH DESIGN AND METHODS: Clinicians used the web-based research data management program REDCap™ to enter patient information into the CLEAR registry.
RESULTS: Dalbavancin was most frequently prescribed for acute bacterial skin and skin structure infections (55.6% of patients) and bone/joint infections (24.4%). Methicillin-resistant Staphylococcus aureus (MRSA) (55.6%) and methicillin-susceptible S. aureus (MSSA) (14.4%) were the most common pathogens treated. Dalbavancin treatment was most frequently initiated on a hospital ward (55.0%) or in the emergency department (26.9%). Dalbavancin therapy was chosen because it was a single-dose treatment (71.4%) or facilitated hospital discharge (16.9%) and was primarily administered without other antimicrobial agents (83.1%) as a single 1500 mg dose (63.0%). Microbiological success (pathogen eradicated/presumed eradicated) and clinical success (cure and/or improvement) rates were 93.8% (106/113) and 86.4% (89/103), respectively, for patients with known outcomes. One adverse event (hypersensitivity) was reported.
CONCLUSIONS: Dalbavancin has established itself as a unique and useful antimicrobial in Canada. CLEAR registry data confirm previously published peer-reviewed studies describing the efficacy and safety of dalbavancin in the treatment of various infections.
RESEARCH DESIGN AND METHODS: Clinicians used the web-based research data management program REDCap™ to enter patient information into the CLEAR registry.
RESULTS: Dalbavancin was most frequently prescribed for acute bacterial skin and skin structure infections (55.6% of patients) and bone/joint infections (24.4%). Methicillin-resistant Staphylococcus aureus (MRSA) (55.6%) and methicillin-susceptible S. aureus (MSSA) (14.4%) were the most common pathogens treated. Dalbavancin treatment was most frequently initiated on a hospital ward (55.0%) or in the emergency department (26.9%). Dalbavancin therapy was chosen because it was a single-dose treatment (71.4%) or facilitated hospital discharge (16.9%) and was primarily administered without other antimicrobial agents (83.1%) as a single 1500 mg dose (63.0%). Microbiological success (pathogen eradicated/presumed eradicated) and clinical success (cure and/or improvement) rates were 93.8% (106/113) and 86.4% (89/103), respectively, for patients with known outcomes. One adverse event (hypersensitivity) was reported.
CONCLUSIONS: Dalbavancin has established itself as a unique and useful antimicrobial in Canada. CLEAR registry data confirm previously published peer-reviewed studies describing the efficacy and safety of dalbavancin in the treatment of various infections.